EA201891341A1 - Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции - Google Patents
Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляцииInfo
- Publication number
- EA201891341A1 EA201891341A1 EA201891341A EA201891341A EA201891341A1 EA 201891341 A1 EA201891341 A1 EA 201891341A1 EA 201891341 A EA201891341 A EA 201891341A EA 201891341 A EA201891341 A EA 201891341A EA 201891341 A1 EA201891341 A1 EA 201891341A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- cytokine
- proteins
- methods
- cytokine graft
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Настоящее раскрытие предусматривает антительно-цитокиновые привитые белки, которые связываются с рецептором интерлейкина 10 и стимулируют передачу внутриклеточных сигналов через него. Предоставленные антительно-цитокиновые привитые белки находят использование в усилении противовоспалительных клеточных ответов и снижении провоспалительного эффекта при лечении, улучшении и профилактике нарушений, связанных с иммунитетом. Дополнительно предоставлены полинуклеотиды и векторы, которые кодируют антительно-цитокиновые привитые белки, и клетки-хозяева, способные продуцировать антительно-цитокиновые привитые белки, а также способы комбинирования антительно-цитокиновых привитых белков с другими терапевтическими средствами при лечении нарушения, связанного с иммунитетом.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562263008P | 2015-12-04 | 2015-12-04 | |
PCT/IB2016/057283 WO2017093947A1 (en) | 2015-12-04 | 2016-12-01 | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201891341A1 true EA201891341A1 (ru) | 2018-11-30 |
Family
ID=57543103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201891341A EA201891341A1 (ru) | 2015-12-04 | 2016-12-01 | Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции |
Country Status (25)
Country | Link |
---|---|
US (3) | US10144768B2 (ru) |
EP (1) | EP3383891A1 (ru) |
JP (2) | JP6794448B2 (ru) |
KR (2) | KR20210016479A (ru) |
CN (1) | CN108602870A (ru) |
AR (1) | AR106908A1 (ru) |
AU (1) | AU2016362777B2 (ru) |
BR (1) | BR112018010937A2 (ru) |
CA (1) | CA3006477A1 (ru) |
CL (1) | CL2018001427A1 (ru) |
CO (1) | CO2018005678A2 (ru) |
CU (1) | CU20180047A7 (ru) |
EA (1) | EA201891341A1 (ru) |
EC (1) | ECSP18041733A (ru) |
IL (1) | IL259529A (ru) |
MA (1) | MA43372A (ru) |
MX (1) | MX2018006778A (ru) |
PE (1) | PE20181358A1 (ru) |
PH (1) | PH12018501160A1 (ru) |
RU (1) | RU2018124307A (ru) |
SA (1) | SA518391711B1 (ru) |
SG (1) | SG11201804259UA (ru) |
TW (1) | TW201726716A (ru) |
UY (1) | UY37003A (ru) |
WO (1) | WO2017093947A1 (ru) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200362058A1 (en) * | 2017-05-24 | 2020-11-19 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
CN110662762A (zh) * | 2017-05-24 | 2020-01-07 | 诺华股份有限公司 | 抗体细胞因子移植蛋白和用于治疗癌症的方法 |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
WO2018215937A1 (en) * | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
CN109521192B (zh) * | 2018-11-27 | 2021-07-13 | 柏荣诊断产品(上海)有限公司 | 一种提高胶乳比浊试剂检测灵敏度的方法 |
JP2022524018A (ja) * | 2019-03-06 | 2022-04-27 | デカ バイオサイエンシーズ, インコーポレイテッド | Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 |
CN117925710A (zh) * | 2019-06-10 | 2024-04-26 | 武田药品工业株式会社 | 用于抗体生产的细胞培养方法和组合物 |
WO2021006605A1 (ko) * | 2019-07-08 | 2021-01-14 | 주식회사 프로젠 | 신규 il-10 변이체 단백질 및 그의 용도 |
CN110472294B (zh) * | 2019-07-19 | 2022-09-30 | 河南科技大学 | 一种嫁接涡旋光束的掩模板的设计方法 |
MX2023000948A (es) | 2020-07-20 | 2023-04-14 | Deka Biosciences Inc | Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10). |
CN116615462A (zh) | 2020-11-23 | 2023-08-18 | 诺华股份有限公司 | 抗体构建体的表达技术 |
WO2022229854A1 (en) | 2021-04-29 | 2022-11-03 | Novartis Ag | Hypersialylating cells |
CN116063570A (zh) * | 2021-11-02 | 2023-05-05 | 广东菲鹏制药股份有限公司 | Il10单体融合蛋白及其应用 |
WO2024131864A1 (zh) * | 2022-12-21 | 2024-06-27 | 广东菲鹏制药股份有限公司 | 一种il-10单体融合蛋白 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
DK0517895T3 (da) | 1990-12-14 | 1997-04-07 | Univ California | Kimæriske kæder til receptorforbundne signaltransduktionsveje |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
EP0770135A1 (en) | 1994-07-29 | 1997-05-02 | Smithkline Beecham Plc | Novel compounds |
JPH11501506A (ja) * | 1994-12-12 | 1999-02-09 | ベス イスラエル デアコネス メディカル センター | キメラ型サイトカインおよびその利用 |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
WO1999043713A1 (en) | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US7279462B1 (en) | 1998-04-27 | 2007-10-09 | Nevagen Llc | Somatic transgene immunization and related methods |
CA2359067C (en) | 1999-01-15 | 2017-03-14 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2270147B2 (en) | 1999-04-09 | 2020-07-22 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
WO2002044197A2 (en) | 2000-12-01 | 2002-06-06 | Fish Eleanor N | Cytokine receptor binding peptides |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
PT1642910E (pt) * | 2000-12-05 | 2012-03-22 | Alexion Pharma Inc | Anticorpos concebidos de modo racional |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
EP2301959A3 (en) | 2002-04-09 | 2013-03-13 | The Scripps Research Institute | Motif-grafted hybrid polypeptides and uses thereof |
ATE382367T1 (de) | 2002-04-09 | 2008-01-15 | Univ Missouri | Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern |
US8603472B2 (en) * | 2002-04-09 | 2013-12-10 | The Curators Of The University Of Missouri | Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide |
US20050008625A1 (en) | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
EP1638581A2 (en) | 2003-03-31 | 2006-03-29 | The Brigham And Women's Hospital, Inc. | Zwitterionic immunomodulators for the treatment of asthma and allergy |
WO2004108078A2 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals Inc. | Rationally designed antibodies |
AU2005207003C1 (en) | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
DK3540062T3 (da) | 2004-11-16 | 2021-06-28 | Humanigen Inc | Immunoglobulin-variabel region kassetteudskiftning |
NZ586701A (en) | 2008-01-03 | 2013-07-26 | Scripps Research Inst | Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2) |
SG173680A1 (en) | 2009-02-24 | 2011-09-29 | Alexion Pharma Inc | Antibodies containing therapeutic tpo/epo mimetic peptides |
MX2012002014A (es) | 2009-08-17 | 2012-06-13 | Roche Glycart Ag | Inmunoconjugados dirigidos. |
WO2011047262A2 (en) | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
KR101802261B1 (ko) | 2009-11-30 | 2017-11-28 | 바이오테스트 아게 | 전신 홍반성 낭창을 치료하기 위한 인간화된 항-il-10 항체 |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
WO2012045334A1 (en) | 2010-10-05 | 2012-04-12 | Synthon Bv | Biologically active il-10 fusion proteins |
AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
CA2824253C (en) | 2011-02-10 | 2019-09-17 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
KR20130118941A (ko) | 2011-02-10 | 2013-10-30 | 로슈 글리카트 아게 | 면역치료법 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
JP2015509091A (ja) | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | ヒト化抗体 |
EP2802603A4 (en) * | 2012-01-09 | 2015-11-04 | Scripps Research Inst | REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF |
ES2848732T3 (es) | 2012-08-07 | 2021-08-11 | Roche Glycart Ag | Inmunoterapia mejorada |
JP2015530983A (ja) | 2012-08-08 | 2015-10-29 | ロシュ グリクアート アーゲー | インターロイキン−10融合タンパク質及びその使用 |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
WO2014110368A1 (en) | 2013-01-11 | 2014-07-17 | The California Institute For Biomedical Research | Bovine fusion antibodies |
EP2964750B1 (en) | 2013-03-08 | 2019-03-06 | The Curators of the University of Missouri | Compositions for use in the treatment of type 1 diabetes |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
PT3019533T (pt) | 2013-07-11 | 2020-04-17 | Scripps Research Inst | Proteínas de fusão de imunoglobulinas de hélices super-enroladas e composições das mesmas |
US20160168231A1 (en) | 2013-07-18 | 2016-06-16 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
AU2014290361B2 (en) | 2013-07-18 | 2019-04-18 | Taurus Biosciences, Llc | Humanized antibodies with ultralong complementarity determining regions |
CN106061997A (zh) * | 2014-02-06 | 2016-10-26 | 豪夫迈·罗氏有限公司 | 白介素‑10免疫缀合物 |
LT3102595T (lt) | 2014-02-06 | 2019-01-25 | F. Hoffmann-La Roche Ag | Interleukino-2 sulieti baltymai ir jų panaudojimas |
-
2016
- 2016-12-01 KR KR1020217003359A patent/KR20210016479A/ko active Application Filing
- 2016-12-01 MA MA043372A patent/MA43372A/fr unknown
- 2016-12-01 US US15/367,003 patent/US10144768B2/en active Active
- 2016-12-01 JP JP2018528732A patent/JP6794448B2/ja not_active Expired - Fee Related
- 2016-12-01 SG SG11201804259UA patent/SG11201804259UA/en unknown
- 2016-12-01 CU CUP2018000047A patent/CU20180047A7/xx unknown
- 2016-12-01 BR BR112018010937-1A patent/BR112018010937A2/pt not_active IP Right Cessation
- 2016-12-01 UY UY0001037003A patent/UY37003A/es not_active Application Discontinuation
- 2016-12-01 WO PCT/IB2016/057283 patent/WO2017093947A1/en active Application Filing
- 2016-12-01 KR KR1020187018601A patent/KR102213790B1/ko active IP Right Grant
- 2016-12-01 PE PE2018001044A patent/PE20181358A1/es unknown
- 2016-12-01 MX MX2018006778A patent/MX2018006778A/es unknown
- 2016-12-01 CN CN201680080872.0A patent/CN108602870A/zh active Pending
- 2016-12-01 RU RU2018124307A patent/RU2018124307A/ru not_active Application Discontinuation
- 2016-12-01 AU AU2016362777A patent/AU2016362777B2/en not_active Ceased
- 2016-12-01 CA CA3006477A patent/CA3006477A1/en not_active Abandoned
- 2016-12-01 EP EP16810069.1A patent/EP3383891A1/en active Pending
- 2016-12-01 EA EA201891341A patent/EA201891341A1/ru unknown
- 2016-12-02 AR ARP160103699A patent/AR106908A1/es unknown
- 2016-12-02 TW TW105139831A patent/TW201726716A/zh unknown
-
2018
- 2018-05-22 IL IL259529A patent/IL259529A/en unknown
- 2018-05-28 CL CL2018001427A patent/CL2018001427A1/es unknown
- 2018-05-29 CO CONC2018/0005678A patent/CO2018005678A2/es unknown
- 2018-05-31 SA SA518391711A patent/SA518391711B1/ar unknown
- 2018-06-01 PH PH12018501160A patent/PH12018501160A1/en unknown
- 2018-06-15 EC ECIEPI201841733A patent/ECSP18041733A/es unknown
- 2018-10-18 US US16/163,857 patent/US11136366B2/en active Active
-
2020
- 2020-11-11 JP JP2020188307A patent/JP2021040637A/ja active Pending
-
2021
- 2021-08-26 US US17/458,028 patent/US20220127321A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891341A1 (ru) | Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции | |
EA201790530A1 (ru) | Агенты, связывающиеся с cd123, и виды их применения | |
EA201890453A1 (ru) | Анти-angptl8 антитела и их применение | |
EP3964527A3 (en) | Combination therapy for cancer | |
MX2020008244A (es) | Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella. | |
EA201790377A1 (ru) | Антитела к глюкагону и их применения | |
MX2019014695A (es) | Proteinas de fusion de interleucina-2 y usos de las mismas. | |
EA202192736A1 (ru) | Антитела, содержащие только тяжелые цепи, которые связываются с псма | |
EA201591072A1 (ru) | Антитела против pdgfr-бета и их применения | |
EA201400625A1 (ru) | Антитела против pd-l1 и их применение | |
EA202091995A1 (ru) | Композиции и способы лечения не связанного с возрастом нарушения слуха у субъекта-человека | |
CU24437B1 (es) | Anticuerpos agonistas de anti-gitr y composiciones de los mismos | |
EA201590085A1 (ru) | Антитела анти-egfr и их применение | |
MX2019009117A (es) | Anticuerpos anti alfa-sinucleina y usos de los mismos. | |
EA201991207A1 (ru) | Новые агонисты tnfr и их применение | |
EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
EA202091557A1 (ru) | Антитела, содержащие только тяжелые цепи, которые связываются с cd22 | |
EA201892440A1 (ru) | Антитела к tl1a и их применения | |
EA202191122A1 (ru) | СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ | |
PH12019502617A1 (en) | Antibody-cytokine engrafted proteins and methods of use for immune related disorders | |
EA202092302A1 (ru) | Антитела к trem-1 и их применения | |
MX2021015337A (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3. | |
SA521422581B1 (ar) | أil-7r جسام مضادة للوحدة الثانوية ألفا واستخداماتها | |
MX2022016342A (es) | Union de anticuerpos multiespecificos a bcma. | |
WO2018129451A3 (en) | Anti-fgfr antibodies and methods of use |